Recital 247, Decision_act (EU) 2004/104

In forcesince 27 Nov 2002

On the basis of the above, the need for deterrence requires that the starting point of the fine determined in recital 238 should be increased by 100 % to EUR 5,0 million as regards Merck. No multiplying factor will be applied to Aventis Pharma/Rhône-Poulenc Biochimie.

3.3.3. Duration of the infringement